New Zealand listed company Pacific Edge has been granted patent for its melanoma cancer detection technology.

It covers technology being used to develop the melanoma prognostic test that will enable clinicians to distinguish aggressive and life threatening melanomas from those that are not as aggressive.

The USA is the third jurisdiction after China and New Zealand to grant patent protection for the â Prognosis Prediction for Melanomaâ test that is in the development stage.